Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 2:13:1060884.
doi: 10.3389/fendo.2022.1060884. eCollection 2022.

Individualized medical treatment options in Cushing disease

Aleksandra Gilis-Januszewska  1 , Anna Bogusławska  1 , Ewelina Rzepka  1 , Witold Ziaja  1 , Alicja Hubalewska-Dydejczyk  1
Affiliations
Review

Individualized medical treatment options in Cushing disease

Aleksandra Gilis-Januszewska et al. Front Endocrinol (Lausanne). .

Abstract

Cushing disease (CD) is caused by a pituitary tumor which oversecretes adrenocorticotropic hormone (ACTH). It is a serious endocrine disease associated with increased mortality and impaired quality of life. The management of CD remains challenging. Although transsphenoidal surgery is the treatment of choice in most cases, in approximately half of CD patients, second or third-line treatment options are needed. Currently, new medical therapies are available which target adrenal steroidogenesis, pituitary somatostatin and dopamine receptors, and glucocorticoid receptors. Selection of which medication to use should be individualized and is determined by many factors including severity of the disease, possible side effects, patients preferences and local availability. The aim of this article is to describe currently available medical therapy to help clinicians individualize the treatment options in the context of recently updated Pituitary Society recommendations.

Keywords: Cushing disease; ketoconazole; osilodrostat; pasireotide; temozolomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Main mechanisms of steroidogenesis inhibition.
See this image and copyright information in PMC

References

    1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. Obes Res (1994) 2(5):486–508. doi: 10.1002/j.1550-8528.1994.tb00097.x - DOI - PubMed
    1. Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. . Treatment of cushing’s syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab (2015) 100(8):2807–31. doi: 10.1210/jc.2015-1818 - DOI - PMC - PubMed
    1. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. . Consensus on diagnosis and management of cushing's disease: a guideline update. Lancet Diabetes Endocrinol (2021) 9(12):847–75. doi: 10.1016/S2213-8587(21)00235-7 - DOI - PMC - PubMed
    1. Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of cushing’s disease. Endocr Rev (2015) 36(4):385–486. doi: 10.1210/er.2013-1048 - DOI - PMC - PubMed
    1. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger J, Chanson P, et al. . The European registry on cushing’s syndrome: 2-year experience. baseline demographic and clinical characteristics. Eur J Endocrinol (2011) 165(3):383–92. doi: 10.1530/EJE-11-0272 - DOI - PubMed

MeSH terms

Substances